Effects of race on lipid-lowering management in hospitalized patients with coronary heart disease

被引:4
|
作者
Dressler, DD
Jacobson, TA
机构
[1] Emory Univ, Sch Med, Dept Med, Div Gen Med, Atlanta, GA 30303 USA
[2] Hosp Med Unit, Atlanta, GA USA
[3] Off Hlth Promot & Dis Prevent, Grady Hlth Syst, Atlanta, GA USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 09期
关键词
D O I
10.1016/j.amjcard.2004.01.052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to determine the association between patient characteristics, specifically race, and the appropriate management of lipid-reducing therapy in patients with coronary heart disease (CHD) discharged from the hospital. Two hundred fifty-eight consecutive patients with diagnoses suggestive of CHD were identified in a large, inner-city university teaching hospital serving a predominantly indigent African American population. The outcome measure, suboptimal lipid management, evaluated the intensification of lipid-reducing therapy when indicated using the National Cholesterol Education Program guidelines for the low-density lipoprotein cholesterol goal. The overall rate of suboptimal lipid management was 48%. Black patients with CHD were significantly more likely to have suboptimal lipid management than nonblack patients by the time of hospital discharge (52.3% vs 16.7%, p = 0.021). The disparity in the clinical management of black patients with CHD may help explain the differential in health outcomes seen between black and white patients. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:1167 / 1170
页数:4
相关论文
共 50 条
  • [11] Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
    Temporelli, Pier Luigi
    Arca, Marcello
    D'Erasmo, Laura
    De Caterina, Raffaele
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 14
  • [12] Trials of lipid-lowering therapy in primary prevention of coronary heart disease
    Jones, PH
    CURRENT OPINION IN LIPIDOLOGY, 1995, 6 (06) : 365 - 368
  • [13] Coronary heart disease benefits from blood pressure and lipid-lowering
    Sever, Peter S.
    Poulter, Neil R.
    Mastorantonakis, Stylianos
    Chang, Choon Lan
    Dahlof, Bjorn
    Wedel, Hans
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 135 (02) : 218 - 222
  • [14] Benefits of lipid-lowering agents in stroke and coronary heart disease: Pharmacoeconomics
    Rockson S.G.
    Current Atherosclerosis Reports, 2000, 2 (2) : 144 - 150
  • [15] Lipid-lowering for prevention of coronary heart disease: What policy now?
    UlHaq, I
    Ramsay, LE
    Pickin, DM
    Yeo, WW
    Jackson, PR
    Payne, JN
    CLINICAL SCIENCE, 1996, 91 (04) : 399 - 413
  • [16] Trials of lipid-lowering therapy in secondary prevention of coronary heart disease
    Olsson, AG
    Pedersen, T
    Bergdahl, B
    CURRENT OPINION IN LIPIDOLOGY, 1995, 6 (06) : 369 - 373
  • [17] Lipid-lowering therapy for patients with or at risk of coronary artery disease
    Kjekshus, J
    Pedersen, TR
    Tobert, JA
    CURRENT OPINION IN CARDIOLOGY, 1996, 11 (04) : 418 - 427
  • [18] Cardiac rehabilitation effects on lipids in coronary artery disease patients on lipid-lowering therapies
    Patibandla, Sushmitha
    Carlow, Andrea
    Rodrigo, Maria
    Zalos, Gloria
    Smith, Kevin
    Cannon, Richard O., III
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A364 - A365
  • [19] In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease - The time is now
    Fonarow, GC
    Ballantyne, CM
    CIRCULATION, 2001, 103 (23) : 2768 - 2770
  • [20] The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes
    Karalis, Dean G.
    CLINICAL CARDIOLOGY, 2008, 31 (06) : 241 - 248